Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH

(DIM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius Stedim Biotech : Good timing to anticipate a continuation of the trend

share with twitter share with LinkedIn share with facebook
09/16/2020 | 02:39am EDT
long trade
Live
Entry price : 285.8€ | Target : 310€ | Stop-loss : 270€ | Potential : 8.47%
The timing appears opportune to go long in shares of Sartorius Stedim Biotech as we anticipate another pick-up in the underlying trend.
Investors have an opportunity to buy the stock and target the € 310.
Sartorius Stedim Biotech : Sartorius Stedim Biotech : Good timing to anticipate a continuation of the trend
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The group's high margin levels account for strong profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • The stock is in a well-established, long-term rising trend above the technical support level at 187.9 EUR

Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Technically, the stock approaches a strong medium-term resistance at EUR 309.4.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • With an expected P/E ratio at 79.21 and 66.21 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • Most analysts recommend that the stock should be sold or reduced.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart
Subsector Medical Equipment, Supplies & Distribution - NEC
1st jan.Capitalization (M$)Investor Rating
SARTORIUS STEDIM BIOTECH102.98%32 786
ABBOTT LABORATORIES23.03%189 199
MEDTRONIC PLC-5.16%144 638
BECTON, DICKINSON AND COMPA..-14.73%67 221
BAXTER INTERNATIONAL INC.-0.78%42 002
HOYA CORPORATION9.95%41 242
DEXCOM, INC.77.98%37 273
TERUMO CORPORATION8.03%30 316
ZIMMER BIOMET HOLDINGS-7.22%28 753
ALIGN TECHNOLOGY, INC.15.03%25 288
WEST PHARMACEUTICAL SERVICE..84.75%20 508
More Results

share with twitter share with LinkedIn share with facebook

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2020 1 824 M 2 142 M 2 142 M
Net income 2020 330 M 388 M 388 M
Net Debt 2020 196 M 230 M 230 M
P/E ratio 2020 83,4x
Yield 2020 0,30%
Capitalization 27 636 M 32 786 M 32 452 M
EV / Sales 2020 15,3x
EV / Sales 2021 13,1x
Nbr of Employees 6 690
Free-Float 25,7%
Upcoming event on SARTORIUS STEDIM BIOTECH
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 7
Average target price 232,43 €
Last Close Price 299,80 €
Spread / Highest target 0,07%
Spread / Average Target -22,5%
Spread / Lowest Target -41,0%
EPS Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman & Chief Executive Officer
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif Executive VP-Research & Development
Henri Riey Independent Non-Executive Director
Anne-Marie Graffin Independent Non-Executive Director